Topical Calcineurin Inhibitors as Second‑Line Therapy for Pediatric Atopic Dermatitis

Indications & Position in the Treatment Hierarchy

The Taiwan Academy of Pediatric Allergy, Asthma and Immunology recommends that, for children ≥ 2 years with atopic dermatitis inadequately controlled by appropriate‑strength topical corticosteroids and emollients, topical calcineurin inhibitors (tacrolimus or pimecrolimus) should be initiated as the next therapeutic step. [@1]
The same Academy positions TCIs as steroid‑sparing immunomodulators to be added before any systemic immunosuppressive therapy, creating a clear hierarchy: optimize topical steroids → add TCIs (or wet‑wrap therapy) → consider systemic options only if needed. [@1]
Systemic corticosteroids are discouraged in pediatric AD because of rebound flares, hypothalamic‑pituitary‑adrenal axis suppression, and are appropriate only for short‑term crisis management (≤ 2 weeks). Guidelines consistently advise against long‑term systemic steroid use in children. [@1]

Tacrolimus ointment is approved in 0.03 % (for mild‑to‑moderate disease) and 0.1 % (for moderate‑to‑severe disease) concentrations for patients ≥ 2 years of age. [@1]
Pimecrolimus 1 % cream is also approved for use in children ≥ 2 years of age. [@1]
Both agents are especially useful for facial and intertriginous areas where topical steroid‑induced skin atrophy is a concern. [@4]

When TCIs are unsuitable or unavailable, wet‑wrap therapy combined with a topical corticosteroid is an effective short‑term (3–7 days, up to 14 days in severe cases) second‑line treatment for moderate to very severe AD. [@1]
The technique involves applying a topical corticosteroid, covering the area with a wet tubular bandage layer, then adding a dry layer on top. [@1]
Implementation requires specialized instruction and often a referral to dermatology for proper training. [@4]

The American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology state that the risk‑benefit ratios of topical pimecrolimus and tacrolimus are comparable to most conventional therapies for chronic relapsing eczema. [@5]
Epidemiologic data show that the observed incidence of lymphoma in patients using topical calcineurin inhibitors is lower than the rate predicted for the general population. [@5]
Contraindications/precautions (per the same societies):

Refer to dermatology or allergy/immunology if disease worsens despite appropriate escalation to TCIs. [@4]
Referral is also indicated when wet‑wrap therapy is being considered, due to the need for specialized instruction. [@4]
Seek specialist input for secondary infections unresponsive to standard treatment or when systemic therapies become necessary. [@1]

Continue liberal and regular emollient use regardless of TCI initiation; emollients provide both short‑ and long‑term steroid‑sparing benefits. [@1]
Ongoing trigger identification and avoidance strategies should be maintained as part of comprehensive AD management. [@1]

Elimination diets should not be employed as the next therapeutic step after failure of topical corticosteroids and emollients in children with atopic dermatitis. American Academy of Dermatology guidance supports this recommendation. 1
Food allergens can act as disease triggers, but dietary modification should be incorporated into a comprehensive trigger‑avoidance plan rather than replace escalation of anti‑inflammatory therapy. Evidence from recent microbiology research underscores this approach. 2

The International Eczema Council advises that before initiating any systemic treatment, clinicians must first optimize topical therapy, ensure thorough patient/caregiver education, and evaluate phototherapy as an alternative option. 1

Confirm that the potency of the topical corticosteroid used is adequate; low‑potency steroids may be insufficient for moderate disease severity. This step is essential before progressing to topical calcineurin inhibitors. 2
Maintain liberal emollient use throughout treatment to provide both short‑ and long‑term steroid‑sparing benefits. 1
Rule out secondary bacterial colonization (e.g., Staphylococcus aureus), which can perpetuate inflammation and reduce response to topical therapies. 1

Refer to a dermatologist when disease worsens despite appropriate escalation to topical calcineurin inhibitors. 1
Refer when secondary infection persists despite standard management or when systemic immunosuppressive therapy becomes necessary. 1

Topical corticosteroids constitute the cornerstone of treatment for allergic/atopic dermatitis and can be used safely when appropriate precautions are taken, according to the American Academy of Dermatology (AAD) and BMJ guidance. 3, 4

In patients with moderate‑to‑severe or widespread dermatitis that does not respond to initial therapy, the recommendation is to step up to medium‑ or high‑potency topical steroids rather than initiating systemic corticosteroids. This approach is endorsed by the AAD. 4
High‑potency topical steroids (e.g., betamethasone dipropionate) achieve a 94 % good‑to‑excellent response rate in severe disease and acute flares, supporting their use before any systemic option. 4
The therapeutic principle is to employ the lowest‑potency steroid that adequately controls the eczema, with brief drug‑free intervals when feasible, to minimize adverse effects. 3

After acute flares are resolved, intermittent maintenance with a medium‑potency topical steroid applied twice weekly reduces subsequent flares and relapses by approximately seven‑fold compared with emollient use alone. This strategy is recommended by the AAD. 4